This article is more than 5 years old. Information may no longer be current.

Bloomage, Medytox create joint venture to develop toxin in China

Bloomage Biotechnology Corporation Limited announced its partnership with the South Korea biotech company Medytox Inc. to establish a joint venture, Medybloom which will develop and promote botulinum toxin type A business in China.

Medytox, currently occupies the highest botulinum toxin A market share in Korea, according to the press release.

The joint venture will register, promote and sell certain products, mainly botulinum toxin, in China.

Bloomage and Medytox each have 50% shareholding interest in Medybloom.

Source: www.bloomagebio-tech.com/